SA PRO
Free Account
Lyell Immunopharma, Inc.LYELNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating
Hold
5 analysts·Limited coverage
20%
Rating Distribution
Strong Buy
00%
Buy
120%
Hold
360%
Sell
120%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 82% higher.

Bear Case
$45.00
+82%
Consensus
$45.00
+82%
Bull Case
$45.00
+82%
Price Range5 analysts
Low
Consensus
High
$45.00
$45.00
Current Target
Current Price
$24.77
Upside to Target
$20.23

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Dec 9, 2025H.C. Wainwright
Lyell Immunopharma upgraded to Buy from Neutral at H.C. Wainwright
Target:$45.00
+58.7%from $28.36
Nov 24, 2025H.C. Wainwright
Lyell Immunopharma price target raised to $20 from $10 at H.C. Wainwright
Target:$20.00
+4.5%from $19.13
Oct 30, 2024Bank of America Securities
Lyell Immunopharma downgraded to Underperform from Buy at BofA
Target:$1.00
+5.5%from $0.95
Nov 14, 2022Morgan Stanley
Morgan Stanley Downgrades Lyell Immunopharma to Equal-Weight, Lowers Price Target to $7
Target:$7.00
+54.5%from $4.53
May 24, 2022Goldman Sachs
Goldman Sachs Maintains Buy on Lyell Immunopharma, Lowers Price Target to $12
Target:$12.00
+199.3%from $4.01

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance